Evidence map›Paper›PMID 30419843›Full record

ArticleBMC medical genetics2018

Multimodal imaging in a pedigree of X-linked Retinoschisis with a novel RS1 variant.

Kirk Stephenson, Adrian Dockery, Niamh Wynne, Matthew Carrigan, Paul Kenna, G Jane Farrar, David Keegan

Open access · goldAbstract read
In one paragraph

Article in BMC medical genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Whole-exome sequencing identifies anExperimental and therapeutic medicine · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Kirk StephensonThe Catherine McAuley Centre, Mater Private Hospital, Nelson Street, Dublin 7, Ireland. kirkstephenson@hotmail.com.ORCID 0000-0002-7462-7725
Adrian DockeryDepartment of Genetics, Trinity College Dublin, Dublin, Ireland.
Niamh WynneThe Research Foundation, The Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
Matthew CarriganDepartment of Genetics, Trinity College Dublin, Dublin, Ireland.
Paul KennaThe Research Foundation, The Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
G Jane FarrarDepartment of Genetics, Trinity College Dublin, Dublin, Ireland.
David KeeganThe Catherine McAuley Centre, Mater Private Hospital, Nelson Street, Dublin 7, Ireland.
Trinity College Dublin · IEMater Misericordiae University Hospital · IERoyal Victoria Eye and Ear Hospital · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo describe the clinical phenotype and genetic cause underlying the disease pathology in a pedigree (affected n = 9) with X-linked retinoschisis (XLRS1) due to a novel RS1 mutation and to assess suitability for novel therapies using multimodal imaging.

methodsThe Irish National Registry for Inherited Retinal Degenerations (Target 5000) is a program including clinical history and examination with multimodal retinal imaging, electrophysiology, visual field testing and genetic analysis. Nine affected patients were identified across 3 generations of an XLRS1 pedigree. DNA sequencing was performed for each patient, one carrier female and one unaffected relative. Pedigree mapping revealed a further 4 affected males.

resultsAll affected patients had a history of reduced visual acuity and dyschromatopsia; however, the severity of phenotype varied widely between the nine affected subjects. The stage of disease was classified as previously described. Phenotypic severity was not linearly correlated with age. A novel RS1 (Xp22.2) mutation was detected (NM_000330: c.413C > A) resulting in a p.Thr138Asn substitution. Protein modelling demonstrated a change in higher order protein folding that is likely pathogenic.

conclusionsThis family has a novel gene mutation in RS1 with clinical evidence of XLRS1. A proportion of the older generation has developed end-stage macular atrophy; however, the severity is variable. Confirmation of genotype in the affected grandsons of this pedigree in principle may enable them to avail of upcoming gene therapies, provided there is anatomical evidence (from multimodal imaging) of potentially reversible early stage disease.

Indexed as

MutationAdolescentAgedAmino Acid SubstitutionBase SequenceDisease ProgressionEye ProteinsFemaleGene ExpressionGenotypeHumansMacular DegenerationMaleMiddle AgedModels, MolecularMultimodal ImagingEye ProteinsRS1 protein, humanInherited maculopathyInherited retinal dystrophyRetinoschisinX-linked Retinoschisis

Identifiers

PMID30419843
PMCPMC6233547
OpenAlexW2901260761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.